Recent data also demonstrated that co-treatment of ovarian cancer cells with a glycolysis inhibitor and a GnRH2 antagonist reduced cell viability and increased apoptosis to a greater extent than each treatment individually (80). Here, GNRH2 is linked to ovarian cancer.